Marco Conti

Dr. Marco Conti


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2023 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
MCMarco Conti
Marco Conti
FMFrancesca Morciano
Francesca Morciano
CRClaudia Rossati
Claudia Rossati
EGElisabetta Gori
Elisabetta Gori
PBPaolo Belli
Paolo Belli
RRRossella Rella
Rossella Rella
Angiosarcoma of the breast is a rare breast cancer, which can arise de novo (primary breast angiosarcoma, PBA) or as a secondary malignancy (secondary breast angiosarcoma, SBA) as a result of a biological insult. In the latter case, it is usually diagnosed in patients with a previous history of radiation therapy following a conserving treatment for breast cancer. Over the years, the advances in early diagnosis and treatment of breast cancer, with increasing use of breast-conserving surgery and radiation therapy (instead of radical mastectomy), brought about an increased incidence of the secondary type. PBA and SBA have different clinical presentations and often represent a diagnostic challenge due to the nonspecific imaging findings. The purpose of this paper is to review and describe the radiological features of breast angiosarcoma, both in conventional and advanced imaging to guide radiologists in the diagnosis and management of this rare tumor.

24 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CPCamilla Panico
Camilla Panico
FFFrancesca Ferrara
Francesca Ferrara
Ramona WoitekRamona Woitek
Ramona Woitek
ADAnna D'Angelo
Anna D'Angelo
VPValerio Di Paola
Valerio Di Paola
RMRiccardo Manfredi
Riccardo Manfredi
Breast cancer (BC) is the most common cancer among women worldwide. Neoadjuvant chemotherapy (NACT) indications have expanded from inoperable locally advanced to early-stage breast cancer. Achieving a pathological complete response (pCR) has been proven to be an excellent prognostic marker leading to better disease-free survival (DFS) and overall survival (OS). Although diagnostic accuracy of MRI has been shown repeatedly to be superior to conventional methods in assessing the extent of breast disease there are still controversies regarding the indication of MRI in this setting. We intended to review the complex literature concerning the tumor size in staging, response and surgical planning in patients with early breast cancer receiving NACT, in order to clarify the role of MRI. Morphological and functional MRI techniques are making headway in the assessment of the tumor size in the staging, residual tumor assessment and prediction of response. Radiomics and radiogenomics MRI applications in the setting of the prediction of response to NACT in breast cancer are continuously increasing. Tailored therapy strategies allow considerations of treatment de-escalation in excellent responders and avoiding or at least postponing breast surgery in selected patients.

24 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MCMarco Conti
Marco Conti
FMFrancesca Morciano
Francesca Morciano
EBEnida Bufi
Enida Bufi
ADAnna D'Angelo
Anna D'Angelo
CPCamilla Panico
Camilla Panico
RMRiccardo Manfredi
Riccardo Manfredi
Neoadjuvant chemotherapy (NACT) today represents a cornerstone in the treatment of locally advanced breast cancer and highly chemo-sensitive tumors at early stages, increasing the possibilities of performing more conservative treatments and improving long term outcomes. Imaging has a fundamental role in the staging and prediction of the response to NACT, thus aiding surgical planning and avoiding overtreatment. In this review, we first examine and compare the role of conventional and advanced imaging techniques in preoperative T Staging after NACT and in the evaluation of lymph node involvement. In the second part, we analyze the different surgical approaches, discussing the role of axillary surgery, as well as the possibility of non-operative management after-NACT, which has been the subject of recent trials. Finally, we focus on emerging techniques that will change the diagnostic assessment of breast cancer in the near future.

3 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VPValerio Di Paola
Valerio Di Paola
GMGiorgio Mazzotta
Giorgio Mazzotta
MCMarco Conti
Marco Conti
SPSimone Palma
Simone Palma
FOFederico Orsini
Federico Orsini
RMRiccardo Manfredi
Riccardo Manfredi
Targeted axillary dissection (TAD) is an axillary staging technique after NACT that involves the removal of biopsy-proven metastatic lymph nodes in addition to sentinel lymph node biopsy (SLNB). This technique avoids the morbidity of traditional axillary lymph node dissection and has shown a lower false-negative rate than SLNB alone. Therefore, marking positive axillary lymph nodes before NACT is critical in order to locate and remove them in the subsequent surgery. Current localization methods include clip placement with intraoperative ultrasound, carbon-suspension liquids, localization wires, radioactive tracer-based localizers, magnetic seeds, radar reflectors, and radiofrequency identification devices. The aim of this paper is to illustrate the management of axillary lymph nodes based on current guidelines and explain the features of axillary lymph node markers, with relative advantages and disadvantages.

29 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RRRossella Rella
Rossella Rella
MCMarco Conti
Marco Conti
EBEnida Bufi
Enida Bufi
CTCharlotte Marguerite Lucille Trombadori
Charlotte Marguerite Lucille Trombadori
Alba Di LeoneAlba Di Leone
Alba Di Leone
PBPaolo Belli
Paolo Belli
(1) Background: To help to refine the accuracy of sentinel lymph node biopsy (SLNB) in breast cancer (BC) patients with biopsy-proven nodal disease prior to neoadjuvant chemotherapy (NACT), a method of marking the biopsy-proven positive LN at diagnosis to enable its removal during surgery was proposed. The aim of this study was to evaluate the accuracy of the Radio-Guided Occult Lesion Localization (ROLL) technique of biopsy-proven metastatic LN in nodal staging after NACT among node-positive BC patients. (2) Methods: Patients with invasive BC and biopsy-proven axillary metastases receiving NACT were enrolled. A clip marker was placed on the sampled LN (clipped lymph node, CLN) before NACT. Before surgery, the ROLL procedure (radioactive tracer injection into CLN under ultrasound guidance) was performed, and the CLN was surgically resected. The correspondence between the CLNs and SLNs was evaluated. The pathologic findings of the CLNs and SLN(s) were compared with remaining axillary nodes at ALND to determine false negative rates (FNRs). (3) Results: Seventy-two patients were analyzed. Surgery successfully identified the CLN in 70/72 procedures (97.2%). For 60/72 patients who underwent ALND, the FNRs dropped from 19.35% for SLNB to 3.13% for CLN biopsy. (4) Conclusions: The ROLL procedure got CLNs is accurate in axillary nodal staging after NACT in node-positive BC patients at diagnosis.

29 July 2024 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
MCMarco Conti
Marco Conti
FMFrancesca Morciano
Francesca Morciano
SASilvia Amodeo
Silvia Amodeo
EGElisabetta Gori
Elisabetta Gori
GRGiovanna Romanucci
Giovanna Romanucci
RRRossella Rella
Rossella Rella
Breast cancer is a complex disease that includes entities with different characteristics, behaviors, and responses to treatment. Breast cancers are categorized into subgroups based on histological type and grade, and these subgroups affect clinical presentation and oncological outcomes. The subgroup of “special types” encompasses all those breast cancers with insufficient features to belong to the subgroup “invasive ductal carcinoma not otherwise specified”. These cancers account for around 25% of all cases, some of them having a relatively good prognosis despite high histological grade. The purpose of this paper is to review and illustrate the radiological appearance of each special type, highlighting insights and pitfalls to guide breast radiologists in their routine work.